Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

78.69 -4.38 (-5.27%)
Official Closing Price Updated: 7:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 Next >
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication 
Via MarketBeat
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage 
Via MarketBeat
Exposures Product Safety
Watch the buy range for Li Auto, MongoDB, Novo Nordisk
Large-cap stocks Li Auto, MongoDB, and Novo Nordisk are in buy range as the S&P 500 rallies. Those stocks boast robust upside momentum in recent weeks 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
BellRing Brands gets pumped on the Ozempic weight-loss trend
Sports nutritional products maker BellRing Brands Inc. (NYSE: BRBR) has seen its stock surge to new all-time highs driven by the popularity of GLP-1 weight-loss 
Via MarketBeat
Will Eli Lilly's Zepbound be the next big weight-loss drug?
Eli Lilly got regulators' OK for weight-loss drug Zepbound, which will compete with Novo Nordisk's Wegovy. Analysts see Zepbound sales as high as $37 billion 
Via MarketBeat
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Can Diabetes, Weight-Loss Drugs Get Even Better?
Via Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027
EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END 
Via FinancialNewsMedia
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Is the Ozempic-Driven DexCom Selloff Overdone?
Has glucose monitor maker DexCom corrected too much on fears of lost sales due to weight loss and diabetes drugs made by Novo Nordisk and Eli Lilly? 
Via MarketBeat
Snack Maker Mondelez Int'l Is Down but Not Out
If Mondelez beats consensus for Q3 and can offer reassurance about the potential impact of Ozempic, investors’ appetite for chewed up snack makers may improve. 
Via MarketBeat
Will Higher Ozempic Use Mean Slimmed-Down Food Sales?
Novo Nordisk's Ozempic, a weight loss drug, is making waves in the food industry, raising concerns about its effect on sales of calorie-laden products. 
Via MarketBeat
Obesity Drug Boom, Split Make This Stock a Heavy Bargain
Ozempic users may be losing their appetites for sweets…but Novo Nordisk is one Danish treat that the market may only get hungrier for. 
Via MarketBeat
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
Exposures Death Product Safety
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?
Eli Lilly & Co. stock has been on a tear, trading up 57.7% year-to-date on the strength of its industry-leading medications and highly-anticipated pipeline 
Via MarketBeat
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
MarketBeat Week in Review – 8/7 - 8/11
The latest inflation readings failed to provide clarity for investors as stocks had a turbulent week and the MarketBeat team was covering the top stories 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results
Novo Nordisk's stock surged 16% on preliminary results of clinical trials showing its weight-loss drug Wegovy reduces risk of cardiovascular disease by 20%. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies. 
Via MarketBeat
InvestorNewsBreaks – Novo Nordisk (NYSE: NVO) Featured in Analysis Report
Via Investor Brand Network
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth. 
Via MarketBeat
Topics Economy
Exposures Economy
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares 
Via MarketBeat
Can Teladoc Stock Be Resuscitated?
Virtual healthcare services company Teladoc Health Inc. (NYSE: TDOC) has had a treacherous journey rising to a high of $308 in Feb 2021 and falling to a post- 
Via MarketBeat
Exposures COVID-19
Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs
The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme 
Via MarketBeat
Novo Nordisk Charges Higher and Could be Just Getting Started
Novo Nordisk stock continues to move higher after announcing a partnership with Aspect Biosystems; but at 47x earnings this is still an expensive stock 
Via MarketBeat
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
Weight management meals and services provider WW International Inc. (NYSE: WW) spike over 25% as it closed its acquisition of telehealth weight loss platform 
Via MarketBeat
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.